Szegedi, Márta <br/><br/>
[Shift of focus in the financing of Hungarian drugs. Reimbursement for orphan drugs for treating rare diseases: financing of enzyme replacement therapy in Hungary].  [electronic resource] 

 -  Orvosi hetilap  Nov 2014 
 - 1735-41 p.  digital 
<br/><br/> Publication Type: English Abstract; Journal Article; Review 
<br/><br/><label>ISSN: </label>0030-6002 
<br/><br/><label>Standard No.: </label>10.1556/OH.2014.30031  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Compassionate Use Trials--economics<br/>Drug Costs<br/>Enzyme Replacement Therapy--economics<br/>Fabry Disease--drug therapy<br/>Financing, Government--legislation & jurisprudence<br/>Gaucher Disease--drug therapy<br/>Glycogen Storage Disease Type II--drug therapy<br/>Health Services Needs and Demand<br/>Humans<br/>Hungary<br/>Insurance Coverage<br/>Insurance, Health<br/>Mucopolysaccharidosis I--drug therapy<br/>Mucopolysaccharidosis II--drug therapy<br/>Orphan Drug Production--economics<br/>Rare Diseases--drug therapy